Board Approves Audited Financial Results
Themis Medicare Limited (BSE: THEMISMED) held a board meeting to consider and approve its audited standalone and consolidated financial results for the quarter and financial year ended 31st March, 2026. The statutory audit was conducted by M/s. Krishaan & Co., Chartered Accountants, who issued their report alongside the results. The audited figures reflect the company's performance across both standalone and consolidated bases for the period under review. Investors tracking the pharmaceutical mid-cap space will find these results significant in assessing Themis Medicare's financial trajectory.
Final Dividend Recommendation
The board has recommended a final dividend of Re. 0.50 per equity share, representing a 50% payout on the face value of Re. 1 each. This dividend recommendation aggregates to Rs. 4,60,50,060 for the Financial Year ended 31st March, 2026. However, this recommendation remains subject to approval from shareholders at the company's forthcoming Annual General Meeting. Dividend-focused investors typically view such recommendations as a positive signal regarding the company's cash position and profitability during the fiscal year.
Cost Auditor Appointment
Themis Medicare has appointed M/s. R. Nanabhoy & Co., Cost Accountants (FRN - 000011) as the Cost Auditor of the Company for the Financial Year 2026-27. The appointment of a cost auditor is a regulatory requirement under the Companies Act, ensuring proper maintenance and audit of cost records. R. Nanabhoy & Co. will be responsible for examining the company's cost accounting records and submitting their report for the upcoming fiscal year, further strengthening corporate governance practices at Themis Medicare.
Key Takeaways for Investors
- Audited standalone and consolidated results approved for Q4 and FY ended March 2026
- Final dividend of 50 paise per share recommended, totalling approximately Rs. 4.60 crore
- Dividend subject to shareholder approval at the ensuing AGM
- M/s. R. Nanabhoy & Co. appointed as Cost Auditor for FY 2026-27
- Statutory audit conducted by M/s. Krishaan & Co., Chartered Accountants
Themis Medicare continues to demonstrate adherence to corporate governance standards through timely board appointments, statutory compliance, and shareholder-friendly policies. The upcoming Annual General Meeting will serve as the platform where shareholders formally approve the dividend proposal. Investors are advised to review the complete audited financial statements once filed with the stock exchanges for a comprehensive understanding of the company's financial health.
This article is for informational purposes only and does not constitute financial advice.Investors should conduct their own research or consult a qualified financial advisor before making investment decisions in Themis Medicare or any other listed security.